secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0000950170-24-014643
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma reports Q2 FY2024 results; cash $59.5M, zero revenue, clinical data readouts expected H1 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments of $59.5M at Dec 31, 2023, with no outstanding debt.
- Revenue zero for Q2 ended Dec 31, 2023 vs $32.7M prior year due to Kyowa Kirin agreement termination.
- R&D expenses fell to $3.9M in Q2 from $15.3M Q2 prior year, driven by zandelisib program wind-down.
- Expects initial safety/efficacy data for voruciclib (CDK9 inhibitor) and ME-344 (mitochondrial inhibitor) in first half of 2024.
- Cash used in operations was $29.5M for six months ended Dec 31, 2023, comparable to $29.1M prior period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024014643/0000950170-24-014643-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024014643/meip-20240213.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-014643

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer